drugset / Trial / NCT04025177
Indomethacin PK-PD in Extremely Preterm Neonates
Phase 2
Withdrawn
University of Manitoba
Health Sciences Centre, Winnipeg, Manitoba · collabSt. Boniface Hospital · collabUniversity at Buffalo · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a phase II open-label study evaluating the pharmacokinetics and pharmacodynamics of targeted early use of indomethacin for PDA treatment in preterm neonates \<27 weeks' gestational age.
Timeline
- Start
- 2020-01
- Primary completion
- 2021-08
- Completion
- 2022-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Indomethacin | Small molecule | 0.1 mg/kg | Intravenous |